Who are VX-661 plus ivacaftor combination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symdeko (Copackaged), LUM/IVA, Elexacaftor / Ivacaftor / Tezacaftor, SUZ, Ivacaftor (VX-770), Initiation of CFTR Modulator.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vx-661-plus-ivacaftor-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

VX-661 plus ivacaftor combination — Competitive Intelligence Brief

VX-661 plus ivacaftor combination (VX-661 plus ivacaftor combination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR modulator. Area: Respiratory.

phase 3 CFTR modulator CFTR Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

VX-661 plus ivacaftor combination (VX-661 plus ivacaftor combination) — Vertex Pharmaceuticals Incorporated. VX-661 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector, and ivacaftor is a CFTR potentiator.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VX-661 plus ivacaftor combination TARGET	VX-661 plus ivacaftor combination	Vertex Pharmaceuticals Incorporated	phase 3	CFTR modulator	CFTR
Symdeko (Copackaged)	TEZACAFTOR	Vertex Pharms	marketed		CFTR	2018-01-01
LUM/IVA	LUM/IVA	Vertex Pharmaceuticals Incorporated	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
Elexacaftor / Ivacaftor / Tezacaftor	Elexacaftor / Ivacaftor / Tezacaftor	Nottingham University Hospitals NHS Trust	marketed	CFTR modulator combination (correctors + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
SUZ	SUZ	Vertex Pharmaceuticals Incorporated	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)
Ivacaftor (VX-770)	Ivacaftor (VX-770)	University of Alabama at Birmingham	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)
Initiation of CFTR Modulator	Initiation of CFTR Modulator	Children's Hospital Medical Center, Cincinnati	marketed	CFTR modulator	CFTR (cystic fibrosis transmembrane conductance regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-06 — Symdeko (Copackaged) · 8354427 · US
2026-12-28 — Symdeko (Copackaged) · 9931334 · US
2026-12-28 — Symdeko (Copackaged) · 9670163 · US
2026-12-28 — Symdeko (Copackaged) · 8754224 · US
2026-12-28 — Symdeko (Copackaged) · 8410274 · US
2027-04-09 — Symdeko (Copackaged) · 10239867 · US
2027-04-09 — Symdeko (Copackaged) · 9974781 · US
2027-04-09 — Symdeko (Copackaged) · 11639347 · US
2027-04-09 — Symdeko (Copackaged) · 10022352 · US
2027-05-01 — Symdeko (Copackaged) · 8598181 · US
2027-05-01 — Symdeko (Copackaged) · 7645789 · US
2027-05-01 — Symdeko (Copackaged) · 8623905 · US
2027-05-20 — Symdeko (Copackaged) · 7495103 · US
2027-06-03 — Symdeko (Copackaged) · 7776905 · US
2027-08-05 — Symdeko (Copackaged) · 8324242 · US
2027-11-12 — Symdeko (Copackaged) · 8415387 · US
2029-08-13 — Symdeko (Copackaged) · 11564916 · US
2029-08-13 — Symdeko (Copackaged) · 10646481 · US
2031-03-25 — Symdeko (Copackaged) · 10081621 · US
2031-03-25 — Symdeko (Copackaged) · 11578062 · US
2033-07-15 — Symdeko (Copackaged) · 10058546 · US
2033-07-15 — Symdeko (Copackaged) · 9012496 · US
2035-04-14 — Symdeko (Copackaged) · 10206877 · US

Sponsor landscape (CFTR modulator class)

Vertex Pharmaceuticals Incorporated · 5 drugs in this class
Chiesi Farmaceutici S.p.A. · 1 drug in this class
Children's Hospital Medical Center, Cincinnati · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VX-661 plus ivacaftor combination — Competitive Intelligence Brief. https://druglandscape.com/ci/vx-661-plus-ivacaftor-combination. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab